Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 273

1.

A heuristic model for working memory deficit in schizophrenia.

Qi Z, Yu GP, Tretter F, Pogarell O, Grace AA, Voit EO.

Biochim Biophys Acta. 2016 Nov;1860(11 Pt B):2696-705. doi: 10.1016/j.bbagen.2016.04.031. Epub 2016 May 10.

PMID:
27177811
2.

Bidirectional Homeostatic Regulation of a Depression-Related Brain State by Gamma-Aminobutyric Acidergic Deficits and Ketamine Treatment.

Ren Z, Pribiag H, Jefferson SJ, Shorey M, Fuchs T, Stellwagen D, Luscher B.

Biol Psychiatry. 2016 Sep 15;80(6):457-68. doi: 10.1016/j.biopsych.2016.02.009. Epub 2016 Feb 13.

3.

KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS.

Abdallah CG, Adams TG, Kelmendi B, Esterlis I, Sanacora G, Krystal JH.

Depress Anxiety. 2016 Aug;33(8):689-97. doi: 10.1002/da.22501. Epub 2016 Apr 6. Review.

PMID:
27062302
4.

Ketamine-Based Anesthetic Protocols and Evoked Potential Monitoring: A Risk/Benefit Overview.

Stoicea N, Versteeg G, Florescu D, Joseph N, Fiorda-Diaz J, Navarrete V, Bergese SD.

Front Neurosci. 2016 Feb 16;10:37. doi: 10.3389/fnins.2016.00037. eCollection 2016.

5.

Gamma band oscillations: a key to understanding schizophrenia symptoms and neural circuit abnormalities.

McNally JM, McCarley RW.

Curr Opin Psychiatry. 2016 May;29(3):202-10. doi: 10.1097/YCO.0000000000000244. Review.

PMID:
26900672
6.

Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.

Gerhard DM, Wohleb ES, Duman RS.

Drug Discov Today. 2016 Mar;21(3):454-64. doi: 10.1016/j.drudis.2016.01.016. Epub 2016 Feb 6. Review.

PMID:
26854424
7.

40 Hz Auditory Steady-State Response Is a Pharmacodynamic Biomarker for Cortical NMDA Receptors.

Sivarao DV, Chen P, Senapati A, Yang Y, Fernandes A, Benitex Y, Whiterock V, Li YW, Ahlijanian MK.

Neuropsychopharmacology. 2016 Aug;41(9):2232-40. doi: 10.1038/npp.2016.17. Epub 2016 Feb 3.

PMID:
26837462
8.

Current Status of Ketamine and Related Therapies for Mood and Anxiety Disorders.

Costi S, Van Dam NT, Murrough JW.

Curr Behav Neurosci Rep. 2015 Dec;2(4):216-225. Epub 2015 Oct 1.

PMID:
26783510
9.

Prefrontal glutamate correlates of methamphetamine sensitization and preference.

Lominac KD, Quadir SG, Barrett HM, McKenna CL, Schwartz LM, Ruiz PN, Wroten MG, Campbell RR, Miller BW, Holloway JJ, Travis KO, Rajasekar G, Maliniak D, Thompson AB, Urman LE, Kippin TE, Phillips TJ, Szumlinski KK.

Eur J Neurosci. 2016 Mar;43(5):689-702. doi: 10.1111/ejn.13159. Epub 2016 Feb 22.

PMID:
26742098
10.

New targets for rapid antidepressant action.

Machado-Vieira R, Henter ID, Zarate CA Jr.

Prog Neurobiol. 2015 Dec 23. pii: S0301-0082(15)30038-1. doi: 10.1016/j.pneurobio.2015.12.001. [Epub ahead of print] Review.

PMID:
26724279
11.

Inducible Nitric Oxide Inhibitors Block NMDA Antagonist-Stimulated Motoric Behaviors and Medial Prefrontal Cortical Glutamate Efflux.

Bergstrom HC, Darvesh AS, Berger SP.

Front Pharmacol. 2015 Dec 15;6:292. doi: 10.3389/fphar.2015.00292. eCollection 2015.

12.

Ketamine produces antidepressant-like effects through phosphorylation-dependent nuclear export of histone deacetylase 5 (HDAC5) in rats.

Choi M, Lee SH, Wang SE, Ko SY, Song M, Choi JS, Kim YS, Duman RS, Son H.

Proc Natl Acad Sci U S A. 2015 Dec 22;112(51):15755-60. doi: 10.1073/pnas.1513913112. Epub 2015 Dec 8.

13.

Prefrontal Cortex and Social Cognition in Mouse and Man.

Bicks LK, Koike H, Akbarian S, Morishita H.

Front Psychol. 2015 Nov 26;6:1805. doi: 10.3389/fpsyg.2015.01805. eCollection 2015. Review.

14.

DNA microarray unravels rapid changes in transcriptome of MK-801 treated rat brain.

Kobayashi Y, Kulikova SP, Shibato J, Rakwal R, Satoh H, Pinault D, Masuo Y.

World J Biol Chem. 2015 Nov 26;6(4):389-408. doi: 10.4331/wjbc.v6.i4.389.

15.

Antidepressant Effect of Combined Ketamine and Electroconvulsive Therapy on Patients With Major Depressive Disorder: A Randomized Trial.

Shams Alizadeh N, Maroufi A, Nasseri K, Sadeghi Najafabadi SH, Mousavi Taghiabad A, Gharibi F, Esfandiari GR.

Iran J Psychiatry Behav Sci. 2015 Sep;9(3):e1578. doi: 10.17795/ijpbs-1578. Epub 2015 Sep 23.

16.

Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review.

Rosenblat JD, McIntyre RS, Alves GS, Fountoulakis KN, Carvalho AF.

Curr Neuropharmacol. 2015;13(5):636-55. Review.

17.

Role of presynaptic phosphoprotein synapsin II in schizophrenia.

Molinaro L, Hui P, Tan M, Mishra RK.

World J Psychiatry. 2015 Sep 22;5(3):260-72. doi: 10.5498/wjp.v5.i3.260.

18.

Ketamine for depression: evidence, challenges and promise.

Zarate CA Jr, Niciu MJ.

World Psychiatry. 2015 Oct;14(3):348-50. doi: 10.1002/wps.20269. No abstract available.

19.

Ketamine Suppresses the Ventral Striatal Response to Reward Anticipation: A Cross-Species Translational Neuroimaging Study.

Francois J, Grimm O, Schwarz AJ, Schweiger J, Haller L, Risterucci C, Böhringer A, Zang Z, Tost H, Gilmour G, Meyer-Lindenberg A.

Neuropsychopharmacology. 2016 Apr;41(5):1386-94. doi: 10.1038/npp.2015.291. Epub 2015 Sep 21.

PMID:
26388147
20.

The Effect of Subchronic Dosing of Ciproxifan and Clobenpropit on Dopamine and Histamine Levels in Rats.

Mahmood D, Pillai KK, Khanam R, Jahan K, Goswami D, Akhtar M.

J Exp Neurosci. 2015 Aug 31;9:73-80. doi: 10.4137/JEN.S27244. eCollection 2015.

Items per page

Supplemental Content

Write to the Help Desk